➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
McKinsey
Medtronic
Colorcon
Merck

Last Updated: May 7, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR WELLCOVORIN

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Wellcovorin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00082706 Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant Active, not recruiting National Cancer Institute (NCI) Phase 2 2003-04-01 RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, gemcitabine, and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving fluorouracil together with leucovorin, gemcitabine, and cisplatin works in treating patients with metastatic or unresectable adenocarcinoma of the urothelium or urachal remnant (part of the bladder).
NCT00082706 Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant Active, not recruiting M.D. Anderson Cancer Center Phase 2 2003-04-01 RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, gemcitabine, and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving fluorouracil together with leucovorin, gemcitabine, and cisplatin works in treating patients with metastatic or unresectable adenocarcinoma of the urothelium or urachal remnant (part of the bladder).
NCT00508872 Folfox-B Study for Patients With Colorectal Liver Metastases Terminated Sanofi Phase 2 2005-11-01 Objective: - To evaluate the efficacy of the use of the combination of oxaliplatin, 5-fluorouracil, leucovorin and bevacizumab (FOLFOX-B) in patients with unresectable colorectal liver metastases, with the objective to downstage hepatic disease and enable complete resection of residual disease. Primary Objective: - To evaluate the resection rate in patients with initially unresectable hepatic colorectal metastases downstaged with FOLFOX-B. Complete resection of all liver lesions is the goal. Secondary Objectives: - To evaluate the probability of complete response, partial response or stable disease. - To evaluate the proportion of patients who are resected, and the proportion of patients achieving an R0 resection (among those receiving surgery). - To correlate survival with downstaging and resection based on metastatic colorectal prognostic score. - To evaluate the disease-free survival and overall survival. - To evaluate the positron emission tomography response rate. - To explore correlations of clinical response with telomerase and hTERT expression.
NCT00508872 Folfox-B Study for Patients With Colorectal Liver Metastases Terminated M.D. Anderson Cancer Center Phase 2 2005-11-01 Objective: - To evaluate the efficacy of the use of the combination of oxaliplatin, 5-fluorouracil, leucovorin and bevacizumab (FOLFOX-B) in patients with unresectable colorectal liver metastases, with the objective to downstage hepatic disease and enable complete resection of residual disease. Primary Objective: - To evaluate the resection rate in patients with initially unresectable hepatic colorectal metastases downstaged with FOLFOX-B. Complete resection of all liver lesions is the goal. Secondary Objectives: - To evaluate the probability of complete response, partial response or stable disease. - To evaluate the proportion of patients who are resected, and the proportion of patients achieving an R0 resection (among those receiving surgery). - To correlate survival with downstaging and resection based on metastatic colorectal prognostic score. - To evaluate the disease-free survival and overall survival. - To evaluate the positron emission tomography response rate. - To explore correlations of clinical response with telomerase and hTERT expression.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Wellcovorin

Condition Name

Condition Name for Wellcovorin
Intervention Trials
Leukemia 4
Stage IVC Colorectal Cancer AJCC v8 3
Stage IVB Colorectal Cancer AJCC v8 3
Stage IV Colorectal Cancer AJCC v8 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Wellcovorin
Intervention Trials
Adenocarcinoma 11
Precursor Cell Lymphoblastic Leukemia-Lymphoma 10
Leukemia, Lymphoid 10
Leukemia 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Wellcovorin

Trials by Country

Trials by Country for Wellcovorin
Location Trials
United States 88
Australia 4
Italy 4
Puerto Rico 1
Germany 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Wellcovorin
Location Trials
Texas 13
Missouri 5
Pennsylvania 4
California 3
Ohio 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Wellcovorin

Clinical Trial Phase

Clinical Trial Phase for Wellcovorin
Clinical Trial Phase Trials
Phase 3 6
Phase 2/Phase 3 1
Phase 2 16
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Wellcovorin
Clinical Trial Phase Trials
Not yet recruiting 16
Recruiting 9
Completed 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Wellcovorin

Sponsor Name

Sponsor Name for Wellcovorin
Sponsor Trials
National Cancer Institute (NCI) 16
M.D. Anderson Cancer Center 13
Washington University School of Medicine 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Wellcovorin
Sponsor Trials
Other 37
NIH 16
Industry 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Boehringer Ingelheim
Merck
Medtronic
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.